Where Are We Now?

A Summary of the Past 30 Years of Low Vision Research and Development (An update presented to the International Low Vision Support Group by Director Dan Roberts) Macular Degeneration Support’s International Low Vision Support Group will soon celebrate its 30th year as a leading outreach to people affected by macular degeneration and other diseases leading [Read More]

First Human Eyeball Transplant Accomplished

Eye specialists at New York University Langone Health have announced success with the first transplantation of a complete human eyeball. High-voltage lineman Aaron James, 46, lost his eye in an electrocution accident on June 10, 2021. His multiple surgeries included a partial face transplant, during which the surgeons decided to also replace his eye. This [Read More]

IZERVAY™, is the Second Treatment Approved by the FDA for Geographic Atrophy 

IZERVAY™ reduced the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. IZERVAY slowed loss of photoreceptors and disease progression as early as six months. Astellas Pharma Inc.  announced on August 5, 2023 that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the [Read More]

Free Updated “GuideMe” Book for AMD Now Online

Similar to a practicing low vision therapist, the GuideMe Book for age-related macular degeneration gathers personal information from the client, then offers guidance and resources unique to the client’s personal needs and goals. Prevent Blindness, a patient advocacy organization preserving vision and eye health for more than 115 years, continues to give the gift of [Read More]

First Treatment For Geographic Atrophy Approved

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults   Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]